CML: Increased qPCR Testing Frequency Reduces Hospital Visits

Share this content:
More frequent qPCR testing and better adherence to kinase inhibitors reduce hospital visits among patients with chronic myeloid leukemia.
More frequent qPCR testing and better adherence to kinase inhibitors reduce hospital visits among patients with chronic myeloid leukemia.

More frequent qPCR testing and better adherence to kinase inhibitors reduce hospital visits among patients with chronic myeloid leukemia (CML), a study published in conjunction with the 2016 American Society of Clinical Oncology (ASCO) meeting has shown.1

Researchers estimated the overall impact of qPCR testing frequency on hospital visits, with respect to direct and indirect impacts, by analyzing data from 1431 patients with newly diagnosed CML included in 2 large U.S. claims databases. Adult patients were included in the analysis if they had continuous health plan coverage for at least 6 months before and at least 12 months after frontline kinase inhibitor (imatinib, nilotinib, or dasatinib) initiation.

Investigators estimated the direct and indirect effects of qPCR testing frequency through kinase inhibitor adherence on the number of inpatient days, inpatient admissions, and emergency room visits.

During the 12-month period that patients were receiving a kinase inhibitor, 36% of patients had 0 qPCR tests, 16% had 1, 15% had 2, 18% had 3, and 16% had 4 tests. The average medication possession ratio, a measure of adherence, was 0.86.

RELATED: Ponatinib Induces Durable Responses in Patients With CML for at Least 4 Years

Researchers found that an increase of 1 qPCR test reduced the number of inpatient admission days by 15.2%.An increase of 1 qPCR test overall reduced the number of inpatient admissions by 14.2% and emergency room visits by 8.6%. The study demonstrated that indirect impact accounted for 14.5%, 18.4%, and 2.8% of the reduction, respectively.         

Reference

  1. Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ. Reduction in hospital visits in patients with chronic myeloid leukemia (CML) with better adherence to tyrosine kinase inhibitors (TKI) and increased molecular monitoring frequency. J Clin Oncol. 2016; 34 (suppl; abstr e18539).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters